Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.60 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.59 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17433466 | 0.91 | RAB9A (0.57) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL17433390 | 0.91 | DYRK1A (0.60) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL17433464 | 0.81 | DYRK1A (0.57) | RAB9ANPC1DYRK1APLCG2 | |
| SCHEMBL5089614 | 0.77 | LRRK2 (0.70) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL17422740 | 0.77 | MEN1 (0.51) | RAB9ANPC1 | |
| SCHEMBL14807437 | 0.77 | MAP3K5 (0.68) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3708649 | 0.76 | RAB9A (0.76) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8290010 | 0.76 | LRRK2 (0.64) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL715950 | 0.75 | DYRK1A (1.00) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL17179427 | 0.75 | RAB9A (0.65) | RAB9ANPC1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170216252-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | SIMON FRASER UNIVERSITY (CA) | 2017-08-03 | — | — | US | disclosed |
| US-20170216252-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | SIMON FRASER UNIVERSITY (CA) | 2017-08-03 | — | — | US | disclosed |
| WO-2016004513-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | SIMON FRASER UNIVERSITY (CA) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216252-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | PDK1, PDK3, PDK2 | RAB9A 4231/4885NPC1 2398/4885CYP1A2 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.